Jan 03, 2024 / 01:00PM GMT
Amy Reilly Dyne Therapeutics Inc.-SVP - Head of Corporate Communications & IR
Good morning, everyone, and Amy Reilly, Senior Vice President, Head of Corporate Communications, and Investor Relations at Dyne. Thank you for joining us for Dyne's virtual event, achieving the promise of force to deliver for patients. Today, we will be presenting Dyne's very first clinical data from our DYNE-101 ACHIEVE Trial in myotonic dystrophy type 1 and our DYNE-251 DELIVER trial in Duchenne muscular dystrophy, which we summarized in the press release issued earlier today.
Before we begin, I'd like to remind everyone that we will be making forward-looking statements today that are subject to the Safe Harbor protections provided under the Private Securities Litigation Reform Act of 1990. Actual results may differ materially from these forward-looking statements as a result of various important factors including those discussed in the risk factors section of our recent 10-Q. These statements represent our views as of today's date, and we disclaim any obligation to update these statements.
Dyne Therapeutics Inc ACHIEVE and DELIVER Clinical Data Update Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers